A ‘perfect storm’ has set this sector up to benefit if Trump’s tariffs go ahead, Bank of America says

Bank of America suggests an overweight position in European pharmaceuticals as a contrarian trade, citing the sector's underperformance and low valuations driven by concerns over Trump's tariffs and drug pricing pressures, despite a U.S. court ruling against the tariffs. The firm believes the market is underestimating major players like Novo Nordisk and that a global growth slowdown, potentially triggered by tariffs, could lead to outperformance in European pharma and Swiss stocks, particularly in food and beverage.

Analysis

Bank of America's European equity strategy division highlights a contrarian investment opportunity within the European pharmaceutical sector, which has notably underperformed, with the regional Stoxx Pharmaceuticals index declining nearly 5% this year despite its typically defensive nature. This contrasts with significant gains in other European defensive sectors like utilities. The underperformance is attributed to a 'perfect storm' of investor concerns, including the potential impact of U.S. tariffs, a previously weak U.S. dollar, and fears of U.S. drug price reductions, collectively pushing European pharma valuations to their lowest levels since 2009. Bank of America suggests these risks, particularly from tariffs, are currently over-discounted by the market, noting that a U.S. Court of International Trade ruling against certain tariffs is already being appealed by the administration. Specifically, major players like Novo Nordisk, whose shares have fallen almost 30% year-to-date, are seen as significantly undervalued, with current pricing perceived as not reflecting existing cash flows or pipeline developments such as oral products for weight loss. A key catalyst for the sector's outperformance is identified as a potential global growth slowdown, which could be triggered if new import duties are enacted. Furthermore, Swiss equities, with substantial exposure to pharmaceuticals and food & beverage, are presented as another area of opportunity, trading near record lows relative to the broader European market and poised for 'rich pickings' should a global economic slowdown materialize, especially given that European cyclical and defensive stocks are generally at 30-year highs.

Key Decisions for Investors

• Investors may consider adopting an overweight stance on European pharmaceutical equities as a contrarian defensive play, capitalizing on the sector's current depressed valuations which are the lowest since 2009.
• Closely monitor U.S. trade policy developments and the progression of tariff implementations, as a consequent global growth slowdown could serve as a significant catalyst for the re-rating and outperformance of the European pharma sector.
• Evaluate specific undervalued companies within European pharma, such as Novo Nordisk, where market sentiment appears to have excessively penalized the stock, and explore potential opportunities in the Swiss market, particularly in pharmaceuticals and food & beverage, which could benefit from a flight to quality amid economic deceleration.